|
Selecting optimal patient candidates to assess the clinical utility of patient-derived xenograft (PDX) models in advanced solid tumors. |
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bristol-Myers Squibb |
|
|
Speakers' Bureau - Bristol-Myers Squibb |
Research Funding - MedImmune |
Travel, Accommodations, Expenses - Caris MPI; Genentech |
|
|
No Relationships to Disclose |
|
|
Employment - Champions Oncology |
Stock and Other Ownership Interests - Champions Oncology |
|
|
Employment - Champions Oncology |
Stock and Other Ownership Interests - Champions Oncology |
|
|
Employment - Champions Oncology |
Leadership - Champions Oncology |
Stock and Other Ownership Interests - Champions Oncology |
|
|
Employment - Champions Oncology |
Leadership - Champions Oncology |
Stock and Other Ownership Interests - Champions Oncology |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Boston Biomedical; Celgene; Novartis; Rockwell Medical |